EGFR Blockade Reverts Resistance to KRAS

Animals Antineoplastic Agents / pharmacology Cell Line, Tumor Cetuximab / pharmacology Colorectal Neoplasms / drug therapy Drug Resistance, Neoplasm / drug effects ErbB Receptors / antagonists & inhibitors Female Humans Mice, SCID Piperazines / pharmacology Protein Kinase Inhibitors / pharmacology Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors Pyridines / pharmacology Pyrimidines / pharmacology

Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
08 2020
Historique:
received: 17 02 2020
revised: 13 04 2020
accepted: 29 04 2020
pubmed: 21 5 2020
medline: 30 11 2021
entrez: 21 5 2020
Statut: ppublish

Résumé

Most patients with

Identifiants

DOI: 10.1158/2159-8290.CD-20-0187 PMID: 32430388 PMC: PMC7416460
pubmed: 32430388
pii: 2159-8290.CD-20-0187
doi: 10.1158/2159-8290.CD-20-0187
pmc: PMC7416460
mid: NIHMS1591958
doi:

Substances chimiques

Antineoplastic Agents 0
KRAS protein, human 0
Piperazines 0
Protein Kinase Inhibitors 0
Pyridines 0
Pyrimidines 0
sotorasib 2B2VM6UC8G
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2
Cetuximab PQX0D8J21J

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1129-1139

Subventions

Organisme : NIH HHS
ID : U54 OD020355
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA233736
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210085
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Organisme : European Research Council
ID : 724748
Pays : International
Organisme : NCATS NIH HHS
ID : UL1 TR000457
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA129243
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

©2020 American Association for Cancer Research.

Références

Drugs. 2018 Jun;78(9):893-911
pubmed: 29915896
Clin Cancer Res. 2019 Oct 15;25(20):6243-6259
pubmed: 31375513
Cancer Discov. 2011 Nov;1(6):508-23
pubmed: 22586653
Sci Transl Med. 2014 Feb 19;6(224):224ra26
pubmed: 24553387
J Clin Oncol. 2007 May 1;25(13):1658-64
pubmed: 17470858
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
ESMO Open. 2016 Sep 16;1(5):e000088
pubmed: 27843640
Nature. 2015 Oct 8;526(7572):263-7
pubmed: 26416732
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20864-9
pubmed: 19106301
Cancer Discov. 2016 Mar;6(3):316-29
pubmed: 26739882
J Clin Oncol. 2005 Mar 20;23(9):1803-10
pubmed: 15677699
Adv Cancer Res. 2010;106:53-89
pubmed: 20399956
Mol Cancer Res. 2015 Sep;13(9):1325-35
pubmed: 26037647
J Clin Oncol. 2004 Apr 1;22(7):1201-8
pubmed: 14993230
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Clin Cancer Res. 2019 Jan 15;25(2):796-807
pubmed: 30327306
J Mol Diagn. 2013 Jul;15(4):454-65
pubmed: 23672976
Clin Cancer Res. 2017 Jan 1;23(1):159-170
pubmed: 27401248
Nature. 2020 Jan;577(7790):421-425
pubmed: 31915379
Sci Rep. 2019 Sep 19;9(1):13568
pubmed: 31537838
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
PLoS One. 2014 Jul 01;9(7):e100586
pubmed: 24983965
Cancer Res. 2017 Dec 1;77(23):6513-6523
pubmed: 28951457
Sci Signal. 2019 May 28;12(583):
pubmed: 31138768
Science. 2016 Feb 5;351(6273):604-8
pubmed: 26841430
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Cell Rep. 2018 Feb 13;22(7):1889-1902
pubmed: 29444439
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Cell. 2017 Jun 29;170(1):17-33
pubmed: 28666118
Cell. 2007 Jun 1;129(5):865-77
pubmed: 17540168
Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S62-70
pubmed: 16336751
Clin Cancer Res. 2020 Apr 1;26(7):1633-1643
pubmed: 31776128
Cell Rep. 2015 Sep 29;12(12):1978-85
pubmed: 26365186
Nat Rev Cancer. 2007 Apr;7(4):295-308
pubmed: 17384584
Cancer Discov. 2012 Mar;2(3):227-35
pubmed: 22448344
Sci Transl Med. 2019 Sep 18;11(510):
pubmed: 31534020
Cell Mol Life Sci. 2016 Dec;73(23):4397-4413
pubmed: 27342992
Nature. 2013 Nov 28;503(7477):548-51
pubmed: 24256730

Auteurs

Vito Amodio (V)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.

Rona Yaeger (R)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Pamela Arcella (P)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.

Carlotta Cancelliere (C)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.

Simona Lamba (S)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.

Annalisa Lorenzato (A)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.

Sabrina Arena (S)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.
ORCID: 0000-0002-1318-2494

Monica Montone (M)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
ORCID: 0000-0001-7907-4333

Benedetta Mussolin (B)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
ORCID: 0000-0001-5723-5685

Yu Bian (Y)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Adele Whaley (A)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Marika Pinnelli (M)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.

Yonina R Murciano-Goroff (YR)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Efsevia Vakiani (E)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Nicola Valeri (N)

Center for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.
Department of Medicine, The Royal Marsden Hospital, London, United Kingdom.

Wei-Li Liao (WL)

mProbe Inc., Rockville, Maryland.

Anuja Bhalkikar (A)

mProbe Inc., Rockville, Maryland.

Sheeno Thyparambil (S)

mProbe Inc., Rockville, Maryland.

Hui-Yong Zhao (HY)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Antitumour Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Elisa de Stanchina (E)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Antitumour Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.

Silvia Marsoni (S)

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Istituto FIRC di Oncologia Molecolare (IFOM), Milan, Italy.

Salvatore Siena (S)

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
ORCID: 0000-0002-2681-2846

Andrea Bertotti (A)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.

Livio Trusolino (L)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.

Bob T Li (BT)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.
ORCID: 0000-0001-6661-8733

Neal Rosen (N)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Molecular-Based Therapy, Memorial Sloan Kettering Cancer Center, New York, New York.

Federica Di Nicolantonio (F)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.
ORCID: 0000-0001-9618-2010

Alberto Bardelli (A)

Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy. misales@mskcc.org alberto.bardelli@unito.it.
Department of Oncology, University of Torino, Candiolo, Torino, Italy.

Sandra Misale (S)

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. misales@mskcc.org alberto.bardelli@unito.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Cétuximab › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris SCID › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipérazines › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › EGFR Blockade Reverts Resistance to KRAS
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › EGFR Blockade Reverts Resistance to KRAS